A glance into the future of anti-neutrophil cytoplasmic antibody-associated vasculitis
In the past decade, unprecedented progress has been made in understanding the pathogenesis, diagnosis, assessment, and treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAVs). International collaborations and input from several fields (e.g. immunology, rheumatology, a...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2022-11-01
|
| Series: | Therapeutic Advances in Musculoskeletal Disease |
| Online Access: | https://doi.org/10.1177/1759720X221125979 |
| _version_ | 1811243555624058880 |
|---|---|
| author | Marta Casal Moura Carolina Branco Joana Martins-Martinho José Luís Ferraro Alvise Berti Estela Nogueira Cristina Ponte |
| author_facet | Marta Casal Moura Carolina Branco Joana Martins-Martinho José Luís Ferraro Alvise Berti Estela Nogueira Cristina Ponte |
| author_sort | Marta Casal Moura |
| collection | DOAJ |
| description | In the past decade, unprecedented progress has been made in understanding the pathogenesis, diagnosis, assessment, and treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAVs). International collaborations and input from several fields (e.g. immunology, rheumatology, and nephrology) have been critical for analyzing demographics, disease manifestations, and outcomes in clinical research studies. Such efforts opened new avenues for generating novel questions and rationale to design better clinical trials. In addition, clinical research has been a source of several biological discoveries and the starting point for knowledge seeking on the pathophysiology of AAV. Interestingly, the blending of clinical and basic research provides a platform for personalized medicine. Despite recent revisions on AAV classification, the incorporation of new findings on disease genetics and immunologic responses may soon result in changes in clinical practice. These advances will enhance the selection of more specific and targeted therapies. However, current unmet needs in the management of AAV are still sizable and heavily impact long-term survival. Especially, frequent relapses, damage accrual, and high morbidity contribute to poor outcomes. Finally, the lack of defined biomarkers for disease activity and the prognosis is a permanent challenge in AAV research. Our work provides an overview of the current state of the art in AAV literature and suggests bridges for the remaining knowledge gaps. It offers potential future directions for the clinical assessment, management, and research in the field toward a more personalized medicine approach. |
| first_indexed | 2024-04-12T14:09:25Z |
| format | Article |
| id | doaj.art-105ab7310d2e49108f3e3e3af25fc023 |
| institution | Directory Open Access Journal |
| issn | 1759-7218 |
| language | English |
| last_indexed | 2024-04-12T14:09:25Z |
| publishDate | 2022-11-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Musculoskeletal Disease |
| spelling | doaj.art-105ab7310d2e49108f3e3e3af25fc0232022-12-22T03:29:56ZengSAGE PublishingTherapeutic Advances in Musculoskeletal Disease1759-72182022-11-011410.1177/1759720X221125979A glance into the future of anti-neutrophil cytoplasmic antibody-associated vasculitisMarta Casal MouraCarolina BrancoJoana Martins-MartinhoJosé Luís FerraroAlvise BertiEstela NogueiraCristina PonteIn the past decade, unprecedented progress has been made in understanding the pathogenesis, diagnosis, assessment, and treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAVs). International collaborations and input from several fields (e.g. immunology, rheumatology, and nephrology) have been critical for analyzing demographics, disease manifestations, and outcomes in clinical research studies. Such efforts opened new avenues for generating novel questions and rationale to design better clinical trials. In addition, clinical research has been a source of several biological discoveries and the starting point for knowledge seeking on the pathophysiology of AAV. Interestingly, the blending of clinical and basic research provides a platform for personalized medicine. Despite recent revisions on AAV classification, the incorporation of new findings on disease genetics and immunologic responses may soon result in changes in clinical practice. These advances will enhance the selection of more specific and targeted therapies. However, current unmet needs in the management of AAV are still sizable and heavily impact long-term survival. Especially, frequent relapses, damage accrual, and high morbidity contribute to poor outcomes. Finally, the lack of defined biomarkers for disease activity and the prognosis is a permanent challenge in AAV research. Our work provides an overview of the current state of the art in AAV literature and suggests bridges for the remaining knowledge gaps. It offers potential future directions for the clinical assessment, management, and research in the field toward a more personalized medicine approach.https://doi.org/10.1177/1759720X221125979 |
| spellingShingle | Marta Casal Moura Carolina Branco Joana Martins-Martinho José Luís Ferraro Alvise Berti Estela Nogueira Cristina Ponte A glance into the future of anti-neutrophil cytoplasmic antibody-associated vasculitis Therapeutic Advances in Musculoskeletal Disease |
| title | A glance into the future of anti-neutrophil cytoplasmic antibody-associated vasculitis |
| title_full | A glance into the future of anti-neutrophil cytoplasmic antibody-associated vasculitis |
| title_fullStr | A glance into the future of anti-neutrophil cytoplasmic antibody-associated vasculitis |
| title_full_unstemmed | A glance into the future of anti-neutrophil cytoplasmic antibody-associated vasculitis |
| title_short | A glance into the future of anti-neutrophil cytoplasmic antibody-associated vasculitis |
| title_sort | glance into the future of anti neutrophil cytoplasmic antibody associated vasculitis |
| url | https://doi.org/10.1177/1759720X221125979 |
| work_keys_str_mv | AT martacasalmoura aglanceintothefutureofantineutrophilcytoplasmicantibodyassociatedvasculitis AT carolinabranco aglanceintothefutureofantineutrophilcytoplasmicantibodyassociatedvasculitis AT joanamartinsmartinho aglanceintothefutureofantineutrophilcytoplasmicantibodyassociatedvasculitis AT joseluisferraro aglanceintothefutureofantineutrophilcytoplasmicantibodyassociatedvasculitis AT alviseberti aglanceintothefutureofantineutrophilcytoplasmicantibodyassociatedvasculitis AT estelanogueira aglanceintothefutureofantineutrophilcytoplasmicantibodyassociatedvasculitis AT cristinaponte aglanceintothefutureofantineutrophilcytoplasmicantibodyassociatedvasculitis AT martacasalmoura glanceintothefutureofantineutrophilcytoplasmicantibodyassociatedvasculitis AT carolinabranco glanceintothefutureofantineutrophilcytoplasmicantibodyassociatedvasculitis AT joanamartinsmartinho glanceintothefutureofantineutrophilcytoplasmicantibodyassociatedvasculitis AT joseluisferraro glanceintothefutureofantineutrophilcytoplasmicantibodyassociatedvasculitis AT alviseberti glanceintothefutureofantineutrophilcytoplasmicantibodyassociatedvasculitis AT estelanogueira glanceintothefutureofantineutrophilcytoplasmicantibodyassociatedvasculitis AT cristinaponte glanceintothefutureofantineutrophilcytoplasmicantibodyassociatedvasculitis |